McAllister, Branduff http://orcid.org/0000-0001-6308-2136
Donaldson, Jasmine http://orcid.org/0000-0001-6699-0674
Binda, Caroline S.
Powell, Sophie http://orcid.org/0000-0002-6507-6079
Chughtai, Uroosa http://orcid.org/0000-0001-8110-7114
Edwards, Gareth
Stone, Joseph http://orcid.org/0000-0003-0767-385X
Lobanov, Sergey http://orcid.org/0000-0002-3126-1903
Elliston, Linda
Schuhmacher, Laura-Nadine
Rees, Elliott
Menzies, Georgina http://orcid.org/0000-0002-6600-6507
Ciosi, Marc http://orcid.org/0000-0002-7663-4080
Maxwell, Alastair
Chao, Michael J.
Hong, Eun Pyo http://orcid.org/0000-0001-7789-686X
Lucente, Diane
Wheeler, Vanessa
Lee, Jong-Min http://orcid.org/0000-0001-5799-0787
MacDonald, Marcy E.
Long, Jeffrey D. http://orcid.org/0000-0001-7181-9652
Aylward, Elizabeth H.
Landwehrmeyer, G. Bernhard
Rosser, Anne E.
Paulsen, Jane S.
Williams, Nigel M.
Gusella, James F.
Monckton, Darren G. http://orcid.org/0000-0002-8298-8264
Allen, Nicholas D. http://orcid.org/0000-0003-4009-186X
Holmans, Peter http://orcid.org/0000-0003-0870-9412
Jones, Lesley http://orcid.org/0000-0002-3007-4612
Massey, Thomas H. http://orcid.org/0000-0002-9804-2131
,
,
Funding for this research was provided by:
Cardiff University
Alzheimer’s Research UK
Wellcome Trust
CHDI Foundation
RCUK | Medical Research Council (MR/L010305/1, MR/L010305/1, MR/P001629/1)
CHDI Foundation
Brain Research Trust (201617-06)
Patrick Berthoud Charitable Trust
Article History
Received: 6 May 2021
Accepted: 11 February 2022
First Online: 4 April 2022
Competing interests
: V.C.W. is a scientific advisory board member of Triplet Therapeutics, a company developing new therapeutic approaches to address triplet repeat disorders such Huntington’s disease and myotonic dystrophy. V.C.W.’s financial interests in Triplet Therapeutics were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. V.C.W. is also a scientific advisory board member of LoQus23 Therapeutics and has provided paid consulting services to Alnylam. J.-M.L. is on the scientific advisory board of GenEdit. J.D.L. is a paid advisory board member for F. Hoffmann-La Roche and uniQure biopharma and is a paid consultant for Vaccinex, Wave Life Sciences, Genentech, Triplet Therapeutics and PTC Therapeutics. E.H.A. serves on a Data Safety Monitoring Board for Roche. G.B.L. has provided consulting services, advisory board functions, clinical trial services and/or lectures for Allergan, Alnylam, Amarin, AOP Orphan Pharmaceuticals, Bayer Pharma, the CHDI Foundation, GlaxoSmithKline, F. Hoffmann-La Roche, Ipsen, Isis Pharma, Lundbeck, Neurosearch, Medesis, Medivation, Medtronic, NeuraMetrix, Novartis, Pfizer, Prana Biotechnology, Sangamo/Shire, Siena Biotech, Temmler Pharma and Teva Pharmaceuticals. G.B.L. has also received research grant support from the CHDI Foundation, the Bundesministerium für Bildung und Forschung, the Deutsche Forschungsgemeinschaft and the European Commission (EU-FP7, JPND). His study site in Ulm has received compensation in the context of the observational Enroll-HD Study from Teva, Isis, F. Hoffmann-Roche and the Gossweiler Foundation. He receives royalties from Oxford University Press and is employed by the State of Baden-Württemberg at the University of Ulm. A.E.R. is chair of the European Huntington’s Disease Network executive committee and is the global PI for Triplet Therapeutics. J.S.P. has provided consulting services, advisory board functions and clinical trial services for Acadia, F. Hoffman-La Roche, Wave Life Sciences and the CHDI Foundation. J.F.G. is a scientific advisory board member and has a financial interest in Triplet Therapeutics. His National Institutes of Health-funded project is using genetic and genomic approaches to uncover other genes that significantly influence when diagnosable symptoms emerge and how rapidly they worsen in Huntington’s disease. The company is developing new therapeutic approaches to address triplet repeat disorders, such Huntington’s disease, myotonic dystrophy and spinocerebellar ataxias. His interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. J.F.G. has also been a consultant for Wave Life Sciences. Within the last 5 years, D.G.M. has been a scientific consultant and/or received honoraria/stock options/research contracts from AMO Pharma, Charles River Laboratories, LoQus23, Small Molecule RNA, Triplet Therapeutics and Vertex Pharmaceuticals. L.J. is a member of the scientific advisory boards of LoQus23 Therapeutics and Triplet Therapeutics. T.H.M. is an associate member of the scientific advisory board of LoQus23 Therapeutics. B.M., J.D., C.S.B., S.P., U.C., G.E., J.S., S.L., L.E., L.-N.S., E.R., G.M., M.C., A.M., M.J.C., E.P.H., D.L., M.E.M., N.M.W., N.D.A. and P.H. have nothing to disclose.